CDMRP Neurofibromatosis Synergistic Idea Award
ID: 355153Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Neurofibromatosis Synergistic Idea Award, a federal grant aimed at supporting innovative research in neurofibromatosis (NF). This award encourages collaborative projects involving two or three Principal Investigators (PIs) to address critical issues in NF research, with a focus on enhancing understanding, diagnosis, and treatment of NF1, NF2, and schwannomatosis. With an estimated total program funding of $6.4 million and a maximum funding limit of $2 million per award, applications are due by October 3, 2024, and must be submitted through eBRAP and Grants.gov. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    Files
    Title
    Posted
    The DOD FY24 Neurofibromatosis Synergistic Idea Award supports innovative research focusing on neurofibromatosis (NF) to enhance understanding, diagnosis, and treatment of NF1, NF2, and schwannomatosis. With a FY24 appropriation of $25 million, the program encourages collaborative projects involving multiple Principal Investigators (PIs) to address critical issues in NF research. Applications are due by October 3, 2024, with funding aimed at high-impact studies relevant to active-duty service members, veterans, and the broader public. The award emphasizes strategic goals like fostering basic research, rapid therapeutic testing, and enhancing research capacity while encouraging diverse approaches, including data science and health services research. Applicants must submit a two-step application process through eBRAP and Grants.gov, including detailed project narratives, supporting documentation, and budget justifications with a maximum funding limit of $2 million per award. Peer reviews will evaluate applications for scientific merit, focusing on synergy among PIs, research strategy, personnel qualifications, and potential impact on NF research and patient care. Programmatic reviews will further assess alignment with DOD health program priorities. This initiative illustrates the government's commitment to advancing medical research and improving health outcomes related to neurofibromatosis.
    Similar Opportunities
    DOD Glioblastoma, Transformative Consortium Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Glioblastoma Transformative Consortium Award, aimed at advancing research to improve outcomes for glioblastoma patients. This grant seeks proposals for innovative, multidisciplinary projects that collectively address a central hypothesis, requiring collaboration among at least four distinct projects and the inclusion of a consumer advocate. With an estimated total program funding of $9 million, the application process includes a pre-application deadline of December 23, 2024, and a full application deadline of January 13, 2025. Interested applicants can reach the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507 for further assistance.
    DoD Combat Readiness - Medical, Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Combat Readiness - Medical Translational Research Award (CRRP TRA) to support high-impact translational research aimed at enhancing medical readiness for military personnel. This funding opportunity seeks proposals that address critical areas such as battlefield diagnostics, treatments for life-threatening injuries, and operational health threats, with an emphasis on projects that leverage existing resources and demonstrate clear relevance to military health. The total estimated funding for this initiative is approximately $3.3 million, with the expectation of awarding around three grants, and key deadlines include pre-applications due by September 4, 2024, and full proposals by December 5, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Biomedical Research Initiative for Next-Gen BioTechnologies - SynBio Control
    Active
    National Science Foundation
    The National Science Foundation (NSF) is offering a grant opportunity titled "Biomedical Research Initiative for Next-Gen BioTechnologies - SynBio Control" aimed at accelerating the translation of synthetic and engineering biology advances into early-stage biomedical technologies. This initiative requires proposals that include a two-phased plan: Phase I focuses on proof of principle research, while Phase II involves exploratory research to translate findings into biomedical applications, with NSF supporting Phase I and the National Institute of Biomedical Imaging and Bioengineering (NIH/NIBIB) supporting Phase II. The total estimated funding for this program is $2.4 million, with an award floor of $300,000 and an expected eight awards to be made. Interested applicants must submit proposals by December 4, 2024, and can reach out to NSF grants.gov support at grantsgovsupport@nsf.gov for assistance.
    Exploratory/Developmental Research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory and developmental research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) through the R21 grant mechanism (Funding Opportunity Number: RFA-NS-25-025). The initiative aims to enhance understanding of the immunological mechanisms, genetic factors, and potential treatment strategies for these autoimmune neuropathies, with a focus on innovative research that could lead to significant advancements in diagnosis and treatment. Approximately $3 million is available to support up to seven research projects, each with a budget of up to $275,000 over a two-year period. Applications are due by October 4, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the TMD Collaborative for Improving Patient-Centered Translational Research (TMD IMPACT), aimed at advancing research on Temporomandibular Disorders (TMD). This initiative seeks to establish a national, interdisciplinary collaborative that will enhance TMD research, improve clinical care, and train future researchers in the field. The funding opportunity will provide a total of $7 million, with an award ceiling of $3.5 million for up to two cooperative agreements, and is expected to be published in Summer 2024, with applications due in Winter 2024. Interested applicants should prepare for the anticipated collaboration and project development in advance of the expected award date of July 1, 2025.
    Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity for clinical trials aimed at addressing unmet needs in rare neurodegenerative diseases through the Notice of Funding Opportunity (NOFO) RFA-FD-25-001. This initiative, mandated by the ACT for ALS Act, seeks to support trials that evaluate the efficacy and safety of products for new indications or changes in labeling, with the goal of increasing the number of approved treatments for these conditions affecting fewer than 200,000 individuals in the U.S. Eligible applicants include various organizations such as higher education institutions and non-profits, with funding amounts capped at $650,000 for standard applications and up to $900,000 for innovative approaches. Interested parties should note that applications will be accepted starting August 23, 2024, with letters of intent and full applications due by October 22, 2024. For further inquiries, applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov.